We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Bial and Eisai have announced the receipt of a positive opinion for Zebinix (eslicarbazepine acetate) from the European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) to treat adults with newly-diagnosed focal onset epilepsy.